Alto Neuroscience, a Los Altos, CA-based neuro-tech company which specializes in precision psychiatry, raises $35M Series B Financing … The company intends to use the funds to advance lead candidates into Phase 2b studies in major depressive disorder … Proceeds from the financing will also be used to progress the company’s artificial intelligence-enabled brain biomarker platform and launch new clinical trials in areas of high unmet medical need. Alto will report Phase 2a data in early 2023 and further anticipates Phase 2b data readouts by early 2024. [Read more…] about Precision psychiatry pioneer Alto Neuroscience raises $35M to advance digital biomarker-to-treatment platform
In neurofeedback treatment for ADHD, individuals learn to alter their typical pattern of brainwave activity, i.e., EEG activity, to one that is consistent with a focused and attentive state.
This is done by collecting EEG data from individuals as they focus on stimuli presented on a computer screen. Their ability to control the stimuli, e.g., keeping the smile on a smiley face keeping a video playing, depends on their maintaining an EEG state that reflects focused attention.
Over time, most individuals better at this. Supporters of neurofeedback argue that learning to alter EEG activity and focus better during training eventually generalizes to real-world tasks that require strong attention skills, e.g., reading, homework, etc.
Although many experts remain skeptical of this approach, despite numerous supportive studies, a recently published meta-analysis of neurofeedback treatment provides important new support. [Read more…] about Meta-analysis finds sustained benefits of neurofeedback for kids with ADHD